On 22 January, Neurotrope, a clinical-stage biopharmaceutical company focused on developing novel therapies to treat neurodegenerative diseases including Alzheimer's disease (AD), announced new results from its Phase II study of Bryostatin-1 for moderate to severe AD. The Phase II study is a randomised, double-blind and placebo-controlled clinical trial evaluating the safety, tolerability and efficacy of Bryostatin-1 for the treatment of moderate to severe AD in US participants not receiving memantine treatment. Research participants received 7 doses of study drug over 12 weeks. Top-line results released last September showed that the Phase II study of Bryostatin-1 failed to meet its primary endpoint. The company conducted then a full review and provided this month its corporate update. Following completion of data analysis, the company said that the study showed improvement in cognitive function based on the change from baseline to week 13 in the Severe Impairment Battery (SIB) total score, which is the primary endpoint, in the bryostatin-1 treatment group of 32 research participants. In the placebo group of 33 research participants, there was also an increase from baseline in the mean SIB at week 13. The company added that it has been awarded a USD 2.7 million grant from the National Institute of Health to support an additional Phase II clinical trial for people with advanced AD.
Neurotrope reports results from its Phase II trial of Bryostatin-1 for moderate to severe AD
22/01/2020